Gemcitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Superficial Bladder Cancer
Conditions
Superficial Bladder Cancer
Trial Timeline
Feb 1, 2004 → Oct 1, 2005
NCT ID
NCT00191711About Gemcitabine
Gemcitabine is a phase 2 stage product being developed by Eli Lilly for Superficial Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00191711. Target conditions include Superficial Bladder Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00337259 | Phase 2 | Terminated |
| NCT00191711 | Phase 2 | Completed |
| NCT00191971 | Phase 2 | Completed |
| NCT00390182 | Phase 1/2 | Completed |
| NCT00491114 | Phase 2 | Completed |
| NCT02046304 | Phase 1 | Completed |
| NCT00146276 | Phase 3 | UNKNOWN |
Competing Products
11 competing products in Superficial Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 33 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Diclofenac gel | Novartis | Approved | 85 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Dalteparin sodium injection | Pfizer | Approved | 84 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 74 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Chemophase | Halozyme Therapeutics | Phase 1 | 30 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 33 |